Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam.
Potential interactions of ranitidine with antipyrine, diazepam, and lorazepam were evaluated. Ten healthy male subjects were injected intravenously with antipyrine (1.2 gm), diazepam (10 mg), or lorazepam (2 mg) on two randomly assigned occasions, once in the otherwise drug-free state and once while concurrently taking a therapeutic ranitidine dose of 150 mg every 12 hr. Kinetic analysis for antipyrine showed no change in elimination t1/2 between trials (mean, 11.6 and 11.5 hr) with no change in volume of distribution (Vd) or total clearance (0.77 and 0.75 ml/min/kg). Diazepam analysis also showed unchanged t1/2 (32.3 and 28.9 hr) with no change in Vd or total clearance (0.42 and 0.39 ml/min/kg). Lorazepam as well had unchanged t1/2 (11.7 and 11.3 hr), Vd, and total clearance (1.52 and 1.65 ml/min/kg). Therefore ranitidine, unlike cimetidine, has no effect on either human hepatic drug oxidation, as measured by antipyrine and diazepam clearance, or human drug conjugation, as measured by lorazepam clearance.
D000328:Adult; D000983:Antipyrine / Q000378:metabolism*; D001711:Biotransformation; D003975:Diazepam / Q000378:metabolism*; D004347:Drug Interactions; D006801:Humans; D007700:Kinetics; D008140:Lorazepam / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D011899:Ranitidine / Q000494:pharmacology*
D011899:Ranitidine; D008140:Lorazepam; D003975:Diazepam; D000983:Antipyrine